ArrePath combines proprietary AI/ML with experimental chemistry to accelerate antibacterial drug discovery. Its platform couples virtual and experimental compound design and testing to identify novel compounds with the attributes required to progress. The company has identified antibiotic hits active against three clinically novel targets and is advancing lead program AP-001 toward development candidate nomination and eventual Phase 1 studies. Recent non-dilutive funding awards from PACE and CARB-X, together with its latest financing, support these development efforts. The new financing will also back expansion of novel compounds active against non-tuberculous mycobacteria (NTM) and programs targeting the outpatient UTI market and hospital-avoidance strategies. ArrePath is headquartered in Princeton, N.J. ArrePath applies a proprietary AI/ML platform and deep phenotypic imaging to discover new classes of anti-infective small molecules with mechanisms distinct from current antibiotics. Its lead program is designed to be active against multidrug-resistant Gram-negative pathogens, including E. coli and Klebsiella pneumoniae. The company plans to advance the lead candidate through IND-enabling studies with a potential first clinical indication of complicated urinary tract infections caused by MDR organisms. Development includes a dual delivery approach—both intravenous and oral—to support use across healthcare settings. ArrePath was awarded a £1 million non-dilutive grant from PACE to support these activities. The company is based in Princeton, N.J. ArrePath develops a proprietary ML-based platform that decodes complex bacterial behavior (so-called 'bacterial autopsies') to identify and optimize anti-infective agents with novel mechanisms of action. The platform couples imaging and machine learning to enable rapid identification and differentiation of compounds early in discovery. Proof-of-concept work from the company’s scientific founder, Zemer Gitai, was published in Cell in June 2020 and has identified compounds with novel dual mechanisms. ArrePath is a Princeton University spin-out and holds an exclusive option to license related intellectual property and novel compounds generated by the platform. The company recently appointed Dr. Lloyd Payne as President and CEO; he brings more than 25 years of scientific and business leadership in anti-infective discovery, including leadership roles at Evotec and founding Euprotec. The new funding is intended to advance initial leads, expand discovery efforts, and enhance the company’s imaging platform and application of machine learning.

Total raised

$21M

Funding rounds

3

Latest round

Grant

Latest activity

Nov 2024